Expression and activation of MAP kinases, ERK1/2, in the human villous trophoblasts.
Mitogen-activated protein kinase (MAP kinase) plays a central role in the signal transduction for diverse cellular responses, such as proliferation, differentiation, stress response and cell death, via activation after binding of growth factors to the respective receptors on the cell membrane. In the human placental tissues, however, little is known about the expression and activation of the classical MAP kinases, extracellular signal-regulated kinase1/2 (ERK1/2). We therefore examined the expression of ERK1/2 in the human chorionic and placental tissues between 5 and 41 weeks of gestation, using Western blotting, immunohistochemistry and in situ hybridization. To explore the activation of ERK1/2 protein, we used an antibody that reacts with both phosphorylated and non-phosphorylated ERK1/2 (total ERK1/2), as well as antibodies that react only with phosphorylated ERK1/2. The expression pattern of phosphorylated ERK1/2 in the trophoblasts was compared with that of various growth factor receptors, such as c-met, IGF-1R, flt-1, EGFR, PDGFR, Bek, and flg. Total ERK1/2 was immunolocalized in the villous cytotrophoblasts (CTs), but not in the syncytiotrophoblasts (STs), throughout pregnancy. In situ hybridization also showed the localization of ERK1 mRNA in the villous CTs. Interestingly, however, phosphorylated ERK1/2 was immunolocalized in the villous CTs only up to 12 weeks of gestation. Western blot also showed the stronger bands of phosphorylated ERK1/2 in the tissues of the first trimester. Among the growth factor receptors, c-met was strongly expressed in the villous CTs during the first trimester, and resembled the expression pattern of phosphorylated ERK1/2. These findings suggest that the MAP kinase pathway is activated in the villous CTs during the first trimester in the human placenta.
Kita
N
N
Department of Obstetrics and Gynecology, Shinshu University School of Medicine, 3-1-1 Asahi, Matsumoto, Nagano, 390-8621, Japan. naokoich@hsp.md.shinshuu.ac.jp
Mitsushita
J
J
Ohira
S
S
Takagi
Y
Y
Ashida
T
T
Kanai
M
M
Nikaido
T
T
Konishi
I
I
D000328:Adult; D015153:Blotting, Western; D002824:Chorionic Villi / Q000737:chemistry / Q000201:enzymology*; D017931:DNA Primers / Q000737:chemistry; D005260:Female; D000091344:Filaggrin Proteins; D005865:Gestational Age; D006801:Humans; D007124:Immunoenzyme Techniques; D017403:In Situ Hybridization; D019950:Mitogen-Activated Protein Kinase 1 / Q000096:biosynthesis* / Q000235:genetics / Q000276:immunology; D048052:Mitogen-Activated Protein Kinase 3; D020928:Mitogen-Activated Protein Kinases / Q000096:biosynthesis* / Q000235:genetics / Q000276:immunology; D016376:Oligonucleotides, Antisense / Q000737:chemistry; D010766:Phosphorylation; D011247:Pregnancy; D012333:RNA, Messenger / Q000378:metabolism; D017978:Receptors, Growth Factor / Q000378:metabolism; D020133:Reverse Transcriptase Polymerase Chain Reaction; D014327:Trophoblasts / Q000737:chemistry / Q000166:cytology / Q000201:enzymology*
D017931:DNA Primers; C000717249:FLG protein, human; D000091344:Filaggrin Proteins; D016376:Oligonucleotides, Antisense; D012333:RNA, Messenger; D017978:Receptors, Growth Factor; D019950:Mitogen-Activated Protein Kinase 1; D048052:Mitogen-Activated Protein Kinase 3; D020928:Mitogen-Activated Protein Kinases